CIRCULATING INTERLEUKIN-1-BETA AND SOLUBLE INTERLEUKIN-2 RECEPTOR - EVALUATION AS MARKERS OF DISEASE-ACTIVITY IN SCLERODERMA
- Author(s)
- PATRICK, MR; KIRKHAM, BW; GRAHAM, M; Harrision, LC;
- Details
- Publication Year 1995-04,Volume 22,Issue #4,Page 654-658
- Journal Title
- JOURNAL OF RHEUMATOLOGY
- Publication Type
- Journal Article
- Abstract
- Objectives. To investigate whether circulating levels of interleukin 1 beta (IL-beta) or soluble interleukin 2 receptor (sIL-2R) reflect clinical disease status and response to therapy in scleroderma. Methods. Plasma IL-1 beta and serum sIL-2R were measured by ELISA in 19 patients with limited cutaneous scleroderma (9 with extraesophageal internal organ involvement), 5 patients with diffuse cutaneous scleroderma and internal organ involvement, and 11 healthy controls, as well as serially over 12 months in 4 patients with scleroderma treated with cyclosporine. Results. IL-1 beta levels were similar in scleroderma and control subject groups, sIL-2R levels were significantly higher in subjects with scleroderma involving internal organs (elevated in 93%), and correlated with erythrocyte sedimentation rate. sIL-2R levels decreased over 12 months in 2 of 4 patients taking cyclosporine in whom other variables remained unchanged. Conclusions. Elevated serum sIL-2R is a marker of internal organ involvement in scleroderma and warrants further investigation in assessing disease prognosis and response to therapy.
- Publisher
- J RHEUMATOL PUBL CO
- Keywords
- PERIPHERAL-BLOOD MONOCYTES; NECROSIS-FACTOR-ALPHA; SYSTEMIC-SCLEROSIS; INTERFERON-GAMMA; CYCLOSPORIN-A; SERUM LEVELS; SKIN; COLLAGEN; CELLS
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 1995-04-01 12:00:00